Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Exit Examination of Volunteers – V 2.0

Posted on By

BA-BE Studies: SOP for Exit Examination of Volunteers – V 2.0

Standard Operating Procedure for Exit Examination of Volunteers in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/084/2025
Supersedes SOP/BA-BE/084/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a uniform and compliant procedure for conducting exit examinations of study volunteers at the end of each period or study completion in Bioavailability/Bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all volunteers participating in BA/BE studies conducted at clinical research facilities, and to the medical personnel conducting post-study medical evaluations prior to discharge.

3. Responsibilities

  • Clinical Research Physician: Conducts physical and clinical assessments at exit.
  • CRC: Coordinates subject flow, maintains records, and ensures form completion.
  • Volunteer Coordinator: Assists in escorting subjects and verifying identity during examination.
See also  BA-BE Studies: SOP for Subject Enrolment and Randomization Process - V 2.0

4. Accountability

The Principal Investigator is accountable for ensuring that exit examinations are performed and documented before subjects are discharged from the study site.

5. Procedure

5.1 Eligibility for Exit Examination

  1. Volunteers are eligible for exit examination:
    • After completion of all pharmacokinetic blood draws
    • Following post-dose observation period and safety monitoring

5.2 Medical Assessment at Exit

  1. Conduct physical examination including:
    • Vital signs (BP, pulse, temperature)
    • General health and any reported symptoms
  2. Record findings in Annexure-1: Volunteer Exit Examination Form.
  3. Assess for any adverse events during the study; document and refer to medical follow-up if needed.

5.3 Laboratory Tests (If Applicable)

  1. Based on protocol requirements or clinical discretion, perform:
    • Post-study hematology/biochemistry
    • ECG or urine drug screening
  2. Record in Annexure-2: Exit Laboratory Report Summary.
See also  BA-BE Studies: SOP for Clinical Trial Budget Preparation and Approvals - V 2.0

5.4 Fitness Certification

  1. Upon satisfactory examination, the physician shall:
    • Certify the subject as “Medically Fit for Discharge”
    • Sign Annexure-3: Fitness Certificate
  2. Subjects not found fit must be retained or referred for further management and documented accordingly.

5.5 Documentation and Volunteer Discharge

  1. CRC collects signed forms, updates CRF and discharge checklist.
  2. Subject receives discharge slip and is allowed to leave the facility.
  3. Maintain copies of all documents in the Trial Master File (TMF).

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • CRF: Case Report Form
  • TMF: Trial Master File

7. Documents

  1. Volunteer Exit Examination Form – Annexure-1
  2. Exit Laboratory Report Summary – Annexure-2
  3. Fitness Certificate – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs & Cosmetics Rules, India
  • Study Protocol
See also  BA-BE Studies: SOP for Preparation of Dossiers for US FDA ANDA Submissions - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Volunteer Exit Examination Form

Subject ID BP Pulse Temp Symptoms Physician Signature
VOL-084 118/78 74 36.6°C None Dr. A. Shah

Annexure-2: Exit Laboratory Report Summary

Subject ID Test Type Date Result Summary Remarks
VOL-084 Hematology 17/04/2025 Normal Cleared

Annexure-3: Fitness Certificate

Subject ID Date Status Physician Remarks
VOL-084 17/04/2025 Medically Fit Dr. Arvind Shah Discharged

Revision History:

Revision Date Revision No. Details Reason Approved By
15/01/2022 1.0 Initial Release Study compliance QA Head
17/04/2025 2.0 Included laboratory tests and fitness certificate annexures Audit feedback QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Creams: SOP for Handling Emergencies in Machine Operations – V 2.0
Next Post: API Manufacturing: SOP for Crystallization Process Control – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version